ASGCT: Analysts see Rocket gene therapy setting 'a new bar’ for efficacy in heart condition
Rocket Pharmaceuticals has shared early data from three patients that tie its gene therapy for an inherited heart disease to a well-tolerated safety profile and what analysts believe “sets a new bar” in terms of efficacy for the condition.
Rocket Pharmaceuticals has shared early data from three patients that tie its gene therapy for an inherited heart disease to a well-tolerated safety profile and what analysts believe “sets a new bar” in terms of efficacy for the condition.
